Skip to content
PubMed This is a summary of 99 peer-reviewed journal articles Updated
Clinical Immunology

Autoinflammatory Syndrome with Immunodeficiency: A Patient Guide

At a Glance

Autoinflammatory syndrome with immunodeficiency causes both excessive inflammation and reduced protection against infections. Care focuses on identifying the inherited or acquired subtype and balancing anti-inflammatory treatment with immune support, infection prevention, and regular monitoring.

Living with an autoinflammatory syndrome with immunodeficiency means navigating a rare and complex medical landscape where the immune system is simultaneously overactive and underactive. In a healthy system, the immune branches work in harmony to identify and eliminate threats while remaining quiet when the body is safe. In these conditions, that balance is broken: one part of the system is “stuck on,” causing the body to attack its own tissues with heat and swelling, while another part is “stuck off,” leaving it unable to defend against common germs [1][2]. (Note: This is a helpful teaching metaphor, though the specific immune defects vary widely by subtype.)

This diagnosis is an umbrella term within the broader field of Inborn Errors of Immunity (IEI). It encompasses several distinct, rare conditions where a single molecular “glitch” disrupts multiple immune pathways. These include inherited germline conditions that typically begin in childhood, such as HA20, APLAID, and HOIL-1 deficiency, as well as acquired somatic conditions like VEXAS syndrome, which usually appears in older adults [3][4]. Because these conditions are so heterogeneous, identifying the specific genetic mutation or likely subtype is a critical step in care, as it helps doctors move away from broad treatments toward targeted therapies that address your unique biological needs [5][6]. However, a negative or inconclusive genetic test does not exclude clinically significant disease.

Managing this dual-nature condition requires a delicate and ongoing balancing act. Treatment often involves using sophisticated medications to quiet the overactive inflammation while simultaneously using protective measures—like antibody infusions or preventative antibiotics—to bolster the underactive side of the immune system [6][7]. Because these diseases can affect the skin, blood, joints, and internal organs, your care is best managed by a multidisciplinary team of specialists who communicate regularly to adjust your plan as your needs change.

Long-term health depends on consistent monitoring to stay ahead of potential complications. This involves regular blood work to track inflammatory markers and immune cell counts, as well as specialized screenings tailored to your specific organ risks or changes in the bone marrow [5][8]. While the path can feel unpredictable, a clear diagnostic framework and a specialized care team provide the foundation needed to manage symptoms effectively and maintain a high quality of life [9][10].

Common questions in this guide

What is autoinflammatory syndrome with immunodeficiency?
It is a group of rare immune-system disorders in which inflammation is too active while the body is also less able to fight infections. Some forms are inherited and begin in childhood, while others are acquired later in life. The exact symptoms and immune problems depend on the subtype.
Which conditions can fall under this diagnosis?
The umbrella can include inherited conditions such as HA20, APLAID, and HOIL-1 deficiency. It can also include acquired VEXAS syndrome, which usually develops in older adults. Genetic and clinical evaluation helps determine which subtype is most likely.
Can I still have this condition if genetic testing is negative?
Yes. A negative or inconclusive genetic test does not rule out clinically significant disease. Doctors interpret testing alongside symptoms, immune findings, inflammation, and other clinical information, and may continue evaluating for a specific subtype.
How is autoinflammatory syndrome with immunodeficiency treated?
Treatment must address both excessive inflammation and infection risk. Depending on the subtype, care may include medicines that reduce inflammation or target the underlying pathway, along with antibody infusions, preventive antibiotics, and other infection precautions. The plan is individualized and may change over time.
What monitoring is needed over time?
Regular blood tests can track inflammation and immune cell counts. Additional screening may focus on organs at risk or changes in the bone marrow. A multidisciplinary team may coordinate immune, inflammatory, blood, genetic, and other care needs.

Get notified when new evidence is published on autoinflammatory syndrome with immunodeficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (10)
  1. 1

    Autoinflammatory Diseases: A Review.

    An J, Marwaha A, Laxer RM

    The Journal of rheumatology 2024; (51(9)):848-861 doi:10.3899/jrheum.2023-1209.

    PMID: 38879186
  2. 2

    Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease.

    Zilberman-Rudenko J, Shawver LM, Wessel AW, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2016; (113(6)):1612-7 doi:10.1073/pnas.1518163113.

    PMID: 26802121
  3. 3

    Haploinsufficiency of A20 (HA20): updates on the genetics, phenotype, pathogenesis and treatment.

    Yu MP, Xu XS, Zhou Q, et al.

    World journal of pediatrics : WJP 2020; (16(6)):575-584 doi:10.1007/s12519-019-00288-6.

    PMID: 31587140
  4. 4

    Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

    Beck DB, Ferrada MA, Sikora KA, et al.

    The New England journal of medicine 2020; (383(27)):2628-2638 doi:10.1056/NEJMoa2026834.

    PMID: 33108101
  5. 5

    How I Treat: Haploinsufficiency of A20.

    Li J, Zhou JY, Carpio Tumba M, et al.

    Journal of human immunity 2026; (2(4)):e20250138 doi:10.70962/jhi.20250138.

    PMID: 42169681
  6. 6

    Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs).

    Nelson CS, Baloh CH

    Allergy and asthma proceedings 2024; (45(5)):332-339 doi:10.2500/aap.2024.45.240070.

    PMID: 39294916
  7. 7

    Guardians of Immunity: Advances in Primary Immunodeficiency Disorders and Management.

    Peddi NC, Vuppalapati S, Sreenivasulu H, et al.

    Cureus 2023; (15(9)):e44865 doi:10.7759/cureus.44865.

    PMID: 37809154
  8. 8

    VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.

    Kreutzinger V, Pankow A, Boyadzhieva Z, et al.

    Journal of clinical medicine 2024; (13(4)) doi:10.3390/jcm13041049.

    PMID: 38398362
  9. 9

    Clinical characteristics and treatment strategies for A20 haploinsufficiency in Japan: a national epidemiological survey.

    Shiraki M, Kadowaki S, Miwa Y, et al.

    Frontiers in immunology 2025; (16()):1548042 doi:10.3389/fimmu.2025.1548042.

    PMID: 40574834
  10. 10

    Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.

    Lawrence MG, Kim VHD, Orange JS, Scherzer R

    The journal of allergy and clinical immunology. In practice 2026; doi:10.1016/j.jaip.2026.07.010.

    PMID: 42447994

This guide is for educational purposes and does not replace medical advice. Your immunology and specialist care team should interpret genetic results, infection risks, and treatment choices for your individual situation.